Cover Image
Market Research Report

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Published by BCC Research Product code 257331
Published Content info 356 Pages
Delivery time: 1-2 business days
Price
Back to Top
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
Published: March 27, 2017 Content info: 356 Pages
Description

Report Highlights

The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%.

Report Includes:

  • An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
  • Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
  • Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
  • Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
  • Evaluation of prostate cancer treatment products by geography, race, and category
  • Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
  • Comprehensive company profiles of major players in the field.

Report Scope

The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments.

Screening for diagnosis, therapy via drug, surgery or radiation is measured and broken down by PSA testing, digital rectal exam (DRE), prostate biopsy, hormone therapy, chemotherapy, immunotherapy, external beam radiation therapy (EBRT), prostatectomy and brachytherapy.

Analyst Credentials

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents
Product Code: PHM113B

Table of Contents

Chapter 1 - Introduction

  • Introduction
    • Study goals and objectives
    • Reasons for doing this study
    • Intended audience
    • Scope of report
    • Information sources
    • Methodology
    • Geographic breakdown
  • Analyst's credentials
  • Related BCC Research reports

Chapter 2 - Summary and Highlights

  • Summary and highlights

Chapter 3 - Overview

  • Overview
    • Introduction
    • U.S. Preventive Services Task Force recommendations
    • Biology of prostate cancer
      • Prostate gland
    • Prostate gland function
      • Growth of the prostate gland
    • Types of prostate cancer
      • Precancerous conditions of the prostate
      • Prostate cancer development and aging
      • Mechanisms of disease development pathophysiology
      • Family history
      • Environmental factors
      • Epidemiology and risk factors
      • Hormones
      • Growth factors
      • Genetics
      • Molecular mechanisms of prostate cancer
      • The Androgen Receptors
      • PTEN
      • p53
      • GSTP genes
      • Prostate-specific antigen
      • Caveolin-1
      • EMSY
      • AMACR
      • KLF6
      • NBS1
      • CHEK2
      • Mismatch repair genes
      • HOXB13 protein coding gene
      • BRCA1 and BRCA2
      • Hereditary prostate cancer
      • Prostate cancer prevention and treatment
    • Conclusion

Chapter 4 - Prostate Cancer information

  • Prostate cancer information
    • Detection and diagnosis
      • Diagnosis
      • Screening, diagnosis and management of prostate cancer
      • Recommendations for prostate cancer early detection
      • Guidelines for prostate cancer screening
      • Prostate cancer screening guidelines: historical perspective
      • Prostate cancer screening
      • Staging and grading of prostate cancer
      • Diagnostic biopsy
      • Test for metastasis
      • New methods in development
      • Imaging strategies for diagnosis of prostate cancer
      • Prostate cancer prognosis and outcomes predictions
    • Conclusion

Chapter 5 - Prostate Cancer Screening and Diagnosis

  • Prostate cancer screening and diagnosis
    • Prostate cancer screening, diagnosis and prognosis
      • Screening controversies
      • PSA tests
      • Digital rectal exam
      • Prostate ultrasound
      • Imaging technologies for prostate cancer
    • Conclusion

Chapter 6 - Prostate Cancer: Therapeutic Interventions

  • Prostate cancer: therapeutic interventions
    • Treatment plan
      • Treatment options
      • Treatment strategies for prostate cancer by stage
      • Surgery
      • Secondary therapy
      • Radiotherapy
      • Interstitial brachytherapy for low-risk cancers
      • External beam radiotherapy
      • Combined radiation therapy
      • Cryotherapy
      • High-intensity focused ultrasound
      • Focal ablation
      • Hormone therapy
      • Androgen deprivation, an adjuvant therapy
      • Chemoprevention and chemotherapy
      • Immunotherapy/therapeutic vaccines
      • Vascular-targeted photodymanic therapy
      • Nutritional therapy
      • Erectile dysfunction
      • Emerging therapies
    • Conclusion

Chapter 7 - Prostate Cancer Therapeutics in the Global Market

  • Prostate cancer therapeutics in the global market
    • What is cancer?
      • Drugs approved for prostate cancer
      • Drug descriptions
      • Other therapeutic agents

Chapter 8 - Global Burden of Cancer

  • Global burden of cancer
    • Global prostate cancer statistics
      • Prostate cancer mortality
      • Prostate cancer burden globally
      • Prostate cancer in the United States
      • Prostate cancer and Canada
      • Prostate cancer and Europe
      • Prostate cancer in Asia
      • Other nations
    • Conclusion

Chapter 9 - Prostate Cancer and Diagnostic Market

  • Prostate cancer and diagnostic market
    • Screening tests
      • PSA testing: yes or no controversy
    • Prostate cancer market size
      • Prostate cancer screening market
      • DRE market
      • Market for prostate biopsy
    • Prostate cancer diagnostic imaging market
      • Imaging market outlook

Chapter 10 - Prostate Cancer Treatment Market

  • Prostate cancer treatment market
    • Treatment plan for prostate cancer
      • Treatment costs associated with prostate cancer
      • Prostate cancer therapies: three leading prostate cancer therapies
      • Prostate cancer surgery and radiotherapy market
      • Prostate cancer surgical device market
      • Radiotherapy market
      • Brachytherapy market
      • Ultrasound market
      • Prostatectomy market
      • Urological market
      • HIFU in the United States
      • Robotic prostatectomy market
      • Prostate cancer device market in Asia and Latin America

Chapter 11 - Prostate Cancer Drugs Market

  • Prostate cancer drugs market
    • Global oncology therapeutics market
      • New approaches to treat prostate cancer
      • Cytotoxic therapies market
      • Prostate cancer incidence and impact on market
      • Current prostate cancer therapeutics
    • Generic prostate cancer drugs
    • Newer therapies on the market
      • Recent drug approvals and market
    • Prostate cancer: therapeutic drugs landscape
      • Market for chemotherapy
      • Market for chemotherapy drugs for prostate cancer
      • Market for hormone therapy
      • Hormone therapy drugs
      • Market for immunotherapy
      • Prostate cancer care market
    • Conclusion

Chapter 12 - Emerging Prostate Cancer Drugs

  • Emerging prostate cancer drugs
    • Emerging products
      • Cabozantinib
      • Xgeva
      • Custirsen
      • Tasquinimod
      • Sprycel
      • TAK-700
      • Prostvac
      • Alpharadin
      • DCVax-Prostate
    • Not approved drugs
      • Avodart
    • Conclusion

Chapter 13 - Prostate Cancer Patents

  • Prostate cancer patents
    • Prostate cancer drug patents expiry
    • Conclusion

Chapter 14 - Selected Company Profiles

  • Selected company profiles
    • Abbott Laboratories
    • Active Biotech AB
    • Algeta
    • Amgen
    • Astellas Pharma US
    • AstraZeneca
    • Atrix Laboratories
    • Bavarian Nordic A/S
    • Bayer HealthCare Pharmaceuticals
    • Bristol-Myers Squibb
    • C.R. Bard
    • CZ BioMed Corp.
    • Dendreon Corp.
    • DiagnoCure
    • Exelixis
    • Exosome Diagnostics
    • GE Healthcare
    • Genomic Health
    • GlaxoSmithKline
    • Hologic
    • Intuitive Surgical
    • Johnson & Johnson
    • Medivation
    • Metamark
    • Millennium Pharmaceuticals
    • Myriad Genetics
    • Northwest Biotherapeutics
    • Oncogenex
    • Opko Health
    • Pfizer
    • Sanofi
    • Siemens AG
    • Spectrum Pharmaceuticals
    • Varian Medical Systems

Appendix References and End

  • References and end notes
    • References
    • End notes

Lists of Tables and Figures

About BCC Research

  • About BCC Research
    • Conditions of purchase
    • Report Subscriptions
    • Custom Analyses

List of Tables

  • TABLE 1: Summary Table: Global prostate cancer market, through 2021 ($ millions)
  • TABLE 2: U.S. Preventive Services Task Force Recommendations, 2008
  • TABLE 3: Growth factors implicated in prostate cancer
  • TABLE 4: Proposed prostate cancer susceptibility loci
  • TABLE 5: Important genes in the development of prostate cancer
  • TABLE 6: Mutated genes and abnormal protein expression
  • TABLE 7: Why PSA testing?
  • TABLE 8: Signs and symptoms (%)
  • TABLE 9: Guideline statements
  • TABLE 10: Prostate cancer: major points
  • TABLE 11: ACS recommendations for the early detection of cancer in average-risk, asymptomatic individuals
  • TABLE 12: Prostate cancer screening
  • TABLE 13: Limitations of PSA testing
  • TABLE 14: PSA test: why and when?
  • TABLE 15: Age-specific reference ranges for serum PSA (NG/ML)
  • TABLE 16: Other causes of changes in PSA level
  • TABLE 17: Improvements to the PSA test
  • TABLE 18: Prostate cancer diagnosis and treatment strategy
  • TABLE 19: Prostate cancer tests
  • TABLE 20: Prostate cancer: local and metastatic symptoms
  • TABLE 21: Diagnostic methods
  • TABLE 22: Treatment options for prostate cancer
  • TABLE 23: Factors for prostate cancer treatment planning
  • TABLE 24: Guide to prostate cancer diagnosis and management
  • TABLE 25: Stage I prostate cancer
  • TABLE 26: Stage II prostate cancer
  • TABLE 27: Stage III prostate cancer
  • TABLE 28: Stage IV prostate cancer
  • TABLE 29: Types of surgeries
  • TABLE 30: Advantages and disadvantages of radical prostatectomy
  • TABLE 31: Advantages and disadvantages of interstitial brachytherapy
  • TABLE 32: Advantages and disadvantages of external beam radiotherapy
  • TABLE 33: Advantages and disadvantages of cryotherapy
  • TABLE 34: Advantages and disadvantages of ultrasound
  • TABLE 35: Hormone therapy
  • TABLE 36: Common cancers: global cancer cases, 2012
  • TABLE 37: Therapeutics for prostate cancer treatment
  • TABLE 38: Approved FDA prostate cancer drugs
  • TABLE 39: Common drugs for treatment of prostate cancer
  • TABLE 40: Xtandi
  • TABLE 41: Xofigo/Alpharadin
  • TABLE 42: Cabozantinib
  • TABLE 43: Therapeutic agents for prostate cancer under clinical development
  • TABLE 44: Global cancer incidence estimates, 2013 (millions)
  • TABLE 45: Cancer in 2013
  • TABLE 46: World cancer statistics for the most common cancers, 2012
  • TABLE 47: Incidence and deaths for prostate cancer, 2013
  • TABLE 48: Prostate cancer incidence and mortality global, 2012 (thousands)
  • TABLE 49: Highest incidence of prostate cancer, by country, 2012
  • TABLE 50: Global estimated prostate cancer deaths: age-standardized mortality rates per 100,000 men, 2012
  • TABLE 51: Global estimated new cases of prostate cancer, 2008--2030
  • TABLE 52: Prostate cancer statistics, 2016
  • TABLE 53: Prostate cancer cases and deaths in the U.S., 2008--2016
  • TABLE 54: Prostate cancer statistics: new cases and deaths in the U.S., by race, 2007-2012
  • TABLE 55: Prostate cancer stage and survival rate
  • TABLE 56: Estimated prostate cancer new cases in the U.S., 2012--2030
  • TABLE 57: Incidence rates by race in the U.S., 2005--2009
  • TABLE 58: Estimated prostate cancer new cases in the U.S., 2020--2030
  • TABLE 59: Mortality rates by race in the U.S., 2005--2009
  • TABLE 60: Distribution and five-year relative survival by stage at diagnosis for males of all races, 2002-- 2008
  • TABLE 61: Relative survival rate for prostate cancer patients
  • TABLE 62: Five-year relative survival by stage at the time of diagnosis
  • TABLE 63: Estimated prostate cancer in Canada, 2015
  • TABLE 64: Estimated prostate cancer mortality in EU27 countries: age-standardized mortality rates per 100,000 men, 2012
  • TABLE 65: Prostate cancer deaths in the U.K.: rate per 100,000 people, 2014
  • TABLE 66: Estimated prostate cancer diagnosed in 2016
  • TABLE 67: Types of diagnostic tests
  • TABLE 68: Global PSA test sales and forecast, through 2021 ($ millions)
  • TABLE 69: U.S. PSA test sales and forecast, through 2021 ($ millions)
  • TABLE 70: European PSA test sales and forecast, through 2021 ($ millions)
  • TABLE 71: Canadian PSA test sales and forecast, through 2021 ($ millions)
  • TABLE 72: Emerging markets PSA test sales and forecast, through 2021 ($ millions)
  • TABLE 73: Global digital rectal examination sales and forecast, through 2021 ($ millions)
  • TABLE 74: U.S. digital rectal examination sales and forecast, through 2021 ($ millions)
  • TABLE 75: ROW digital rectal examination sales and forecast (excluding the U.S.), through 2021 ($ millions)
  • TABLE 76: Global estimated cost and forecast of prostate biopsies, through 2021 ($ millions)
  • TABLE 77: U.S. estimated cost and forecast of prostate biopsies, through 2021 ($ millions)
  • TABLE 78: ROW estimated cost and forecast of prostate biopsies (excluding the U.S.), through 2021 ($ millions)
  • TABLE 79: Global estimated cost and forecast for prostate biopsies, by region, through 2021 ($ millions)
  • TABLE 80: Global prostate cancer screening sales and forecast, through 2021 ($ millions)
  • TABLE 81: Manufacturers/suppliers of prostate cancer diagnostics market, 2016 ($ millions)
  • TABLE 82: Newer tests and characteristics
  • TABLE 83: List of available prostate nomograms
  • TABLE 84: Global market for prostate cancer imaging technologies: sales and forecast, through 2021 ($ millions)
  • TABLE 85: Prostate cancer therapeutic options when local therapy fails
  • TABLE 86: Cost of the three leading prostate cancer therapies, 2012
  • TABLE 87: Key players of surgical device and radiotherapy companies
  • TABLE 88: Global prostate cancer surgery and radiotherapy market sales and forecast, through 2021 ($ millions)
  • TABLE 89: Global market for external beam radiation therapy sales and forecast, through 2021 ($ millions)
  • TABLE 90: Global brachytherapy market sales and forecast, through 2021 ($ millions)
  • TABLE 91: Global estimated incidence of prostate cancer, 2008--2030 (thousands)
  • TABLE 92: Global estimated cases of prostate surgeries performed per year, 2011-2021 (thousands)
  • TABLE 93: Global market for prostate surgeries sales and forecast, through 2021 ($ millions)
  • TABLE 94: Global cases of estimated robotic prostatectomies performed per year, 2011--2021 (thousands)
  • TABLE 95: Global market for robotic prostatectomy sales and forecast, through 2021 ($ millions)
  • TABLE 96: Global market for estimated open prostatectomy surgeries per year, 2011--2021 (thousands)
  • TABLE 97: Global market for open prostatectomy sales and forecast, through 2021 ($ millions)
  • TABLE 98: U.S. urological device market sales and forecast, through 2016 ($ billions)
  • TABLE 99: U.S. brachytherapy market sales and forecast, through 2021 ($ millions)
  • TABLE 100: Prostate cancer incidence in the U.S., 2008--2016 (thousands)
  • TABLE 101: U.S. total estimated prostatectomy cases, 2011--2021 (thousands)
  • TABLE 102: U.S. robotic prostatectomy market sales and forecast, through 2021 ($ millions)
  • TABLE 103: U.S. prostatectomy surgeries sales and forecast, through 2021 ($ millions)
  • TABLE 104: U.S. open prostatectomy market sales and forecast, through 2021 ($ millions)
  • TABLE 105: Global cancer therapeutic market, through 2021 ($ millions)
  • TABLE 106: Oncology pipeline, 2016
  • TABLE 107: Global cytotherapeutics market, 2010 and 2016 ($ millions)
  • TABLE 108: Cytotoxic therapies market indications
  • TABLE 109: Expiry of patents on major cytotoxic drugs
  • TABLE 110: U.S. cytotherapeutics market, through 2016 ($ millions)
  • TABLE 111: European cytotherapeutics market, through 2016 ($ millions)
  • TABLE 112: Japanese cytotherapeutics market, through 2016 ($ millions)
  • TABLE 113: Major cytotoxic brands sales, 2016 ($ millions)
  • TABLE 114: Drug products and treatment market for prostate cancer, through 2021 ($ millions)
  • TABLE 115: Current prostate cancer therapies and costs
  • TABLE 116: Prostate cancer drug market, through 2021 ($ millions)
  • TABLE 117: Prostate cancer drug products, by treatment category, through 2021 ($ millions)
  • TABLE 118: U.S. prostate cancer market: patients and treatment strategies
  • TABLE 119: New drugs and sales forecast, 2015 and 2021 ($ millions)
  • TABLE 120: Global sales and forecast: key prostate cancer drugs, 2010--2016 ($ millions)
  • TABLE 121: Global prostate cancer chemotherapy drugs
  • TABLE 122: Global chemotherapy market for prostate cancer sales and forecast, through 2021 ($ millions)
  • TABLE 123: Key chemotherapeutic drugs for prostate cancer sales and forecast, 2010--2016 ($ millions)
  • TABLE 124: Global prostate cancer hormonal therapy drugs
  • TABLE 125: Hormone therapy for prostate cancer sales and forecast, through 2021 ($ millions)
  • TABLE 126: Generics sales and forecast, through 2021 ($ millions)
  • TABLE 127: Casodex sales and forecast, through 2021 ($ millions)
  • TABLE 128: Zytiga sales estimates, 2012 and 2015 ($ millions)
  • TABLE 129: Global sales and forecast for Zytiga, through 2021 ($ millions)
  • TABLE 130: Global market sales and forecast for Xtandi, through 2021 ($ millions)
  • TABLE 131: Global market for Flutamide, 2009--2010 ($ millions)
  • TABLE 132: Global market for Triptorelin, 2009--2010 ($ millions)
  • TABLE 133: Global market for Lupron, through 2021 ($ millions)
  • TABLE 134: Global market for Zoladex sales and forecast, through 2021 ($ millions)
  • TABLE 135: Global prostate cancer immunotherapy drug sales and forecast, through 2021 ($ millions)
  • TABLE 136: Provenge annual sales and forecast, 2010--2016 ($ millions)
  • TABLE 137: Global market for prostate cancer care, by region, through 2021 ($ millions)
  • TABLE 138: European prostate cancer care market, through 2021 ($ millions)
  • TABLE 139: U.S. prostate cancer care market, through 2021 ($ millions)
  • TABLE 140: Canadian prostate cancer care market, through 2021 ($ millions)
  • TABLE 141: Global prostate cancer market sales and forecast, through 2021 ($ millions)
  • TABLE 142: Emerging products for prostate cancer
  • TABLE 143: Prostate cancer patent trends, 2002--2011
  • TABLE 144: Patents by treatment category, 2002--2011
  • TABLE 145: Expiry of patents on major brands
  • TABLE 146: List of key Dendreon patents and patent applications

List of Figures

  • FIGURE 1: Summary Figure: Global prostate cancer market, 2012-2021 ($ millions)
  • FIGURE 2: Chemical structure of Casodex
  • FIGURE 3: Chemical structure of Zoladex
  • FIGURE 4: Chemical structure of Eligard
  • FIGURE 5: Chemical structure of Nilandron
  • FIGURE 6: Chemical structure of Flutamide
  • FIGURE 7: Chemical structure of Trelstar
  • FIGURE 8: Chemical structure of Estramustine
  • FIGURE 9: Chemical structure of Firmagon
  • FIGURE 10: Chemical structure of Docetaxel
  • FIGURE 11: Chemical structure of Jevtana
  • FIGURE 12: Chemical structure of Zytiga
  • FIGURE 13: Chemical structure of Xtandi
  • FIGURE 14: Global cancer incidence estimates, 2013 (millions)
  • FIGURE 15: Prostate cancer incidence and mortality global, 2012 (thousands)
  • FIGURE 16: Global estimated prostate cancer deaths: age-standardized mortality rates per 100,000 men, 2012
  • FIGURE 17: Global estimated new cases of prostate cancer, 2008--2030
  • FIGURE 18: Prostate cancer cases and deaths in the U.S., 2008--2016
  • FIGURE 19: Estimated prostate cancer new cases in the U.S., 2012--2030
  • FIGURE 20: Estimated prostate cancer new cases in the U.S., 2020--2030
  • FIGURE 21: Estimated prostate cancer mortality in EU27 countries: age-standardized mortality rates per 100,000 men, 2012
  • FIGURE 22: Prostate cancer deaths in the U.K.: rate per 100,000 people, 2014
  • FIGURE 23: Global PSA test sales and forecast, 2010-2021 ($ millions)
  • FIGURE 24: U.S. PSA test sales and forecast, 2011-2021 ($ millions)
  • FIGURE 25: European PSA test sales and forecast, 2011-2021 ($ millions)
  • FIGURE 26: Canadian PSA test sales and forecast, 2011-2021 ($ millions)
  • FIGURE 27: Emerging markets PSA test sales and forecast, 2010-2021 ($ millions)
  • FIGURE 28: Global digital rectal examination sales and forecast, 2012-2021 ($ millions)
  • FIGURE 29: U.S. digital rectal examination sales and forecast, 2016 and 2021 ($ millions)
  • FIGURE 30: ROW digital rectal examination sales and forecast (excluding the U.S.), 2012-2021 ($ millions)
  • FIGURE 31: Global estimated cost and forecast of prostate biopsies, 2012-2021 ($ millions)
  • FIGURE 32: U.S. estimated cost and forecast of prostate biopsies, 2012-2021 ($ millions)
  • FIGURE 33: ROW estimated cost and forecast of prostate biopsies (excluding the U.S.), 2012-2021 ($ millions)
  • FIGURE 34: Global estimated cost and forecast for prostate biopsies, by region, 2012-2021 ($ millions)
  • FIGURE 35: Global prostate cancer screening sales and forecast, 2012-2021 ($ millions)
  • FIGURE 36: Global market for prostate cancer imaging technologies: sales and forecast, 2012-2021 ($ millions)
  • FIGURE 37: Global prostate cancer surgery and radiotherapy market sales and forecast, 2012-2021 ($ millions)
  • FIGURE 38: Global market for external beam radiation therapy sales and forecast, 2012-2021 ($ millions)
  • FIGURE 39: Global brachytherapy market sales and forecast, 2012-2021 ($ millions)
  • FIGURE 40: Global estimated incidence of prostate cancer, 2008--2030 (thousands)
  • FIGURE 41: Global estimated cases of prostate surgeries performed per year, 2011-2021 (thousands)
  • FIGURE 42: Global market for prostate surgeries sales and forecast, 2012-2021 ($ millions)
  • FIGURE 43: Global cases of estimated robotic prostatectomies performed per year, 2011--2021 (thousands)
  • FIGURE 44: Global market for robotic prostatectomy sales and forecast, 2012-2021 ($ millions)
  • FIGURE 45: Global market for estimated open prostatectomy surgeries per year, 2011--2021 (thousands)
  • FIGURE 46: Global market for open prostatectomy sales and forecast, 2012-2021 ($ millions)
  • FIGURE 47: U.S. brachytherapy market sales and forecast, 2012-2021 ($ millions)
  • FIGURE 48: Prostate cancer incidence in the U.S., 2008--2016 (thousands)
  • FIGURE 49: U.S. robotic prostatectomy market sales and forecast, 2011-2021 ($ millions)
  • FIGURE 50: U.S. prostatectomy surgeries sales and forecast, 2012-2021 ($ millions)
  • FIGURE 51: U.S. open prostatectomy market sales and forecast, 2012-2021 ($ millions)
  • FIGURE 52: Global cancer therapeutic market, 2016 and 2021 ($ millions)
  • FIGURE 53: U.S. cytotherapeutics market, 2010-2016 ($ millions)
  • FIGURE 54: European cytotherapeutics market, 2010-2016 ($ millions)
  • FIGURE 55: Japanese cytotherapeutics market, 2010-2016 ($ millions)
  • FIGURE 56: Drug products and treatment market for prostate cancer, 2012-2021 ($ millions)
  • FIGURE 57: Prostate cancer drug market, 2012-2021 ($ millions)
  • FIGURE 58: Prostate cancer drug products, by treatment category, 2012-2021 ($ millions)
  • FIGURE 59: Global chemotherapy market for prostate cancer sales and forecast, 2010-2021 ($ millions)
  • FIGURE 60: Hormone therapy for prostate cancer sales and forecast, through 2021 ($ millions)
  • FIGURE 61: Casodex sales and forecast, 2011-2021 ($ millions)
  • FIGURE 62: Zytiga sales estimates, 2012 and 2015 ($ millions)
  • FIGURE 63: Global sales and forecast for Zytiga, 2011-2021 ($ millions)
  • FIGURE 64: Global market for Zoladex sales and forecast, 2009-2021 ($ millions)
  • FIGURE 65: Global prostate cancer immunotherapy drug sales and forecast, 2010-2021 ($ millions)
  • FIGURE 66: Provenge annual sales and forecast, 2010--2016 ($ millions)
  • FIGURE 67: Global market for prostate cancer care, by region, 2012-2021 ($ millions)
  • FIGURE 68: European prostate cancer care market, 2012-2021 ($ millions)
  • FIGURE 69: U.S. prostate cancer care market, 2012-2021 ($ millions)
  • FIGURE 70: Canadian prostate cancer care market, 2012-2021 ($ millions)
  • FIGURE 71: Global prostate cancer market sales and forecast, through 2021 ($ millions)
Back to Top